Literature DB >> 15725397

Inhibition of MG132-induced mitochondrial dysfunction and cell death in PC12 cells by 3-morpholinosydnonimine.

Chung Soo Lee1, Eun Sook Han, Eon Sob Park, Hyoweon Bang.   

Abstract

The effect of 3-morpholinosydnonimine (SIN-1) against the cytotoxicity of MG132, a proteasome inhibitor, in differentiated PC12 cells was assessed by measuring the effect on the mitochondrial membrane permeability. Treatment of PC12 cells with MG132 resulted in the nuclear damage, decrease in the mitochondrial transmembrane potential, cytosolic accumulation of cytochrome c, activation of caspase-3, increase in the formation of reactive oxygen species (ROS), and depletion of GSH. Addition of SIN-1, a producer of nitric oxide (NO) and superoxide, differentially reduced the MG132-induced cell death and GSH depletion concentration dependently with a maximal inhibitory effect at 150 microM. Carboxy-PTIO, superoxide dismutase, Mn-TBAP, and ascorbate prevented the inhibitory effect of SIN-1 on the cytotoxicity of MG132. SIN-1 inhibited the MG132-induced change in the mitochondrial membrane permeability, ROS formation and decrease in GSH contents in PC12 cells. S-nitroso-N-acetyl-DL-penicillamine reduced the MG132-induced cell death in PC12 cells, whereas peroxynitrite and H2O2 did not affect the cytotoxicity of MG132. The results suggest that NO and superoxide liberated from SIN-1 exert an inhibitory effect against the cytotoxicity of MG132. SIN-1 may inhibit the MG132-induced viability loss in PC12 cells by suppressing change in the mitochondrial membrane permeability that is associated with oxidative damage.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15725397     DOI: 10.1016/j.brainres.2004.12.036

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  8 in total

1.  Depressant effect of mitochondrial respiratory complex inhibitors on proteasome inhibitor-induced mitochondrial dysfunction and cell death in PC12 cells.

Authors:  Sun-Joo Lee; Young Chul Youn; Eun Sook Han; Chung Soo Lee
Journal:  Neurochem Res       Date:  2005-09       Impact factor: 3.996

2.  Reductions of the components of the calreticulin/calnexin quality-control system by proteasome inhibitors and their relevance in a rodent model of Parkinson's disease.

Authors:  Xiu-Li Kuang; Fang Liu; Huifang Chen; Yiping Li; Yimei Liu; Jian Xiao; Ge Shan; Mingjie Li; B Joy Snider; Jia Qu; Steven W Barger; Shengzhou Wu
Journal:  J Neurosci Res       Date:  2014-05-23       Impact factor: 4.164

3.  Half-life of DISC1 protein and its pathological significance under hypoxia stress.

Authors:  Sandeep Kumar Barodia; Sang Ki Park; Koko Ishizuka; Akira Sawa; Atsushi Kamiya
Journal:  Neurosci Res       Date:  2015-03-01       Impact factor: 3.304

4.  Lewy bodies.

Authors:  Clifford W Shults
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-31       Impact factor: 11.205

5.  LINC00092 Modulates Oxidative Stress and Glycolysis of Breast Cancer Cells via Pyruvate Carboxylase-Mediated AKT/mTOR Pathway.

Authors:  Wei Chen; Yushan Liu; Shaohong Kang; Xinying Lv; Wenfen Fu; Jie Zhang; Chuangui Song
Journal:  Oxid Med Cell Longev       Date:  2022-06-28       Impact factor: 7.310

Review 6.  The Proteasome Inhibition Model of Parkinson's Disease.

Authors:  Eduard Bentea; Lise Verbruggen; Ann Massie
Journal:  J Parkinsons Dis       Date:  2017       Impact factor: 5.568

7.  The Protective Effect of Repeated 1MeTIQ Administration on the Lactacystin-Induced Impairment of Dopamine Release and Decline in TH Level in the Rat Brain.

Authors:  Agnieszka Wąsik; Irena Romańska; Agnieszka Zelek-Molik; Irena Nalepa; Lucyna Antkiewicz-Michaluk
Journal:  Neurotox Res       Date:  2018-08-20       Impact factor: 3.911

8.  Neuroprotective Effects of Cryptotanshinone in a Direct Reprogramming Model of Parkinson's Disease.

Authors:  Joo-Eun Lee; Hyuna Sim; Hee Min Yoo; Minhyung Lee; Aruem Baek; Young-Joo Jeon; Kang-Sik Seo; Mi-Young Son; Joo Seog Yoon; Janghwan Kim
Journal:  Molecules       Date:  2020-08-07       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.